Loading clinical trials...
Loading clinical trials...
Early Concomitant Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial
Conditions
Interventions
Vedolizumab 300 MG Injection [Entyvio]
Prednisone (and methylprednisolone)
+5 more
Locations
2
United States
Brigham and Women's Hospital
Boston, Massachusetts, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Start Date
July 15, 2025
Primary Completion Date
July 30, 2026
Completion Date
December 31, 2026
Last Updated
November 4, 2025
Lead Sponsor
Shilpa Grover, MD, MPH
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions